CORRECTED VERSION

(51) **International Patent Classification**[7]: **C07D 221/20**, 491/10, 471/10, 471/06, 401/06

(21) **International Application Number:**
PCT/IB2005/000751

(22) **International Filing Date:** 16 March 2005 (16.03.2005)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
60/557,598 29 March 2004 (29.03.2004) US

(71) **Applicant** *(for JP only)*: **PFIZER JAPAN INC.** [JP/JP]; Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,, Tokyo 151-8589,japan (JP).

(71) **Applicant** *(for all designated States except JP, US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **HASHIZUME, Yoshinobu** [JP/JP]; Pfizer Global Reseach and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **HIROTA, Masako** [JP/JP]; Pfizer Global Research and Development, Nagoya, Pfizer Japan Inc., 2 Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **MIHARA, Sachiko** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **NAKAMURA, Hiroshi** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-yen 470-2393 (JP). **KOIKE, Hiroki** [JP/JP]; Pfizer Global Research and development, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **MATSUMOTO, Yukari** [JP/JP]; Pfizer Global Research and development, Nagoya, Pfizer Japan Inc., 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).

(74) **Agent: FULLER, Grover, F., Jr.**; Pfizer Inc., 201 Tabor Road, Morris Plains,NJ 07950 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) **Date of publication of the international search report:**
2 March 2006

(48) **Date of publication of this corrected version:**
20 April 2006

(15) **Information about Correction:**
see PCT Gazette No. 16/2006 of 20 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST

(I)

(57) **Abstract:** This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 independently represent a hydrogen atom or the like; R^3 represents a hydrogen atom, or the like; R^4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R^5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxgen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

WO 2005/092858 A3